Citadel Advisors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Citadel Advisors’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-107,953	Closed	-$65K	–	14132
2022 Q2	$65K	Buy	+107,953	New	+$103K	﹤0.01%	11769
2022 Q1	–	Sell	-37,452	Closed	-$98K	–	15107
2021 Q4	$98K	Buy	37,452 +23,545	+169%	+$71.2K	﹤0.01%	12749
2021 Q3	$43K	Sell	13,907 -26,477	-66%	-$88.4K	﹤0.01%	13449
2021 Q2	$150K	Buy	40,384 +26,660	+194%	+$88.7K	﹤0.01%	12509
2021 Q1	$47K	Sell	13,724 -8,969	-40%	-$36.4K	﹤0.01%	12930
2020 Q4	$76K	Buy	22,693 +7,166	+46%	+$25.7K	﹤0.01%	10374
2020 Q3	$54K	Sell	15,527 -137	-0.9%	-$552	﹤0.01%	9578
2020 Q2	$72K	Buy	+15,664	New	+$69.4K	﹤0.01%	9149

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PTP

Platform Technology Partners New York $519M AUM 20% 1-Year Est. Return

Citadel Advisors's PHAS Position: Q3 2022 in Review

Citadel Advisors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2022, closing a stake of 107,953 shares — an estimated $65K sold.

Citadel Advisors first reported a position in PHAS in Q2 2020 and held it in 8 quarters. The position peaked at $150K in Q2 2021. 38 funds tracked by Wall St. Rank hold PHAS as of Q3 2022.

Citadel Advisors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Citadel Advisors sold 107,953 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2022, an estimated $65K.
Citadel Advisors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 8 quarters.
Citadel Advisors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $150K in Q2 2021.
38 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.